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INTRODUCTION 
Wounds are one of the most widespread human afflictions. A good analogy to a wound is the 
common cold; everyone gets one sooner or later, and the body usually heals normally on its 
own, but no one really understands exactly how. For thousands of years, wound healing has 
been the subject of a variety of treatments that have included mud packs, honey, and fire (1, p. 
1064). The presence of a handful of growth factors at the wound site led to the discovery that 
they are responsible for every step of the healing process, from the inflammatory response to 
the erection of a barrier to infection. The underlying mechanisms that control the actions of the 
growth factors, however, are still not perfectly understood. 
I became interested in growth factor activity primarily through my research under the 
tutelage of Dr. Jeff MacCabe, a professor of zoology at the University of Tennessee, Knoxville. 
Although my research does not deal directly with wound healing, I have been able to show 
that basic fibroblast growth factor (bFGF) increases the survival rate of cultured 3T3 fibroblast 
cells (2, unpublished). As I plan to enter medical school in the fall of 1993, I am also particu-
larly interested in growth factors because of their possible clinical applications in alleviating 
pain, helping to heal stubborn chronic wounds, or even speeding up the normal healing pro-
cess itself. Additionally, the disruption of the growth factor mechanism is tied to a number of 
pathologies. Perhaps the further elucidation of the growth factor mechanism might lead to 
possible new treatments for these diseases. Finally, the possibility for both clinical application 
and financial gain has led to cutting-edge research and cut-throat competition among biotech-
nology companies. Some of the questions I will attempt to answer in this paper are: what are 
the specific actions of platelet-derived growth factor (PDGF) and bFGF; how, when, and where 
are they elicited; what are their mechanisms for the transduction of their signal to the recipient 
cell; and what are their impacts on the clinical applications of synthetic growth factors. I will 
also discuss societal issues such as the production of synthetic growth factors, the ethics be-
hind the right to patent them, and where the future of growth factor research might be di-
rected. 
METHODS 
The primary sources of information that I used in researching and producing this paper were 
identified with the use of Medline and General Science Index versions of CD-ROM databases. 
Additional information was gathered using the on-line card catalog from Hodges Library at 
the University of Tennessee, Knoxville, and through personal conversations with Dr. Jeff 
MacCabe, professor of zoology, UTK, and Dr. John Koontz, professor of biochemistry, UTK. 
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HISTORY OF GROWTH FACTORS 
In the most general sense, growth factors can be anything that causes biological cells to grow. 
Specifically, the growth factors bFGF and PDGF discussed in this paper are biological proteins 
that are synthesized by cells and give a pleiotropic response. Their actions include the initia-
tion of cell proliferation, or mitogenesis, an increase in cell migration, or chemotaxis, cell dif-
ferentiation, and a general increase in cell and tissue survival (3, p. xi). 
The first growth factor activity discovered was that of nerve growth factor (NGF) in 
1952 by Rita Levi-Montalcini who described "the widespread presence of a factor endowed 
with nerve growth" associated with mouse sarcomas (4, p. 1156). In the next two years NGF 
was isolated from snake venom by Stanley Cohen (4, p. 1156). Both Cohen and Levi-Montalcini 
shared the Nobel Prize in 1986 for their work with NGF and epidermal growth factor (EGF) (5, 
p. 111). Since their initial discovery more than forty years ago, intense research has led to the 
description of more than 100 growth factors today (6). Some, like NGF, were discovered be-
cause their synthesis was stuck "on" and were found by analyzing sarcomas and other uncon-
trolled growth formations. The growth factor genes may also mutate to produce oncogenes. In 
fact, some growth factors are only known by their oncogenes (7). Still other growth factors are 
discovered by physical force. That is, if a serum is known to have a particular effect on cells, 
then parts of the serum are removed until the effect can be attributed to a specific component 
of the serum. Careful analysis of the extracellular fluid taken from healing wounds has also led 
to the discovery of some growth factors (8, p. 223). Once isolated, growth factors are named for 
where they were discovered. For instance, PDGF was first found in platelets and bFGF was 
first found in fibroblast cells. Their names do not make much sense anymore, however, since 
they are now known to be found just about anywhere in the body in some concentration (7). 
BIOLOGICAL BACKGROUND 
With the ever-increasing number of growth factors that have been described, and the amount 
of research presently being done, similarities begin to emerge among the growth factors so that 
they can often be grouped into families. The primary method of grouping growth factors into 
families is by comparing their amino acid sequences. For instance, the bFGF family includes 
seven members that have similar amino acid sequences even though they are all from different 
genes. The type of receptor used to bind a growth factor and transduce its signal is also a char-
acteristic which separates growth factors into families. Every member of the FGF family and 
the PDGF family have receptors with an intrinsic tyrosine kinase activity. 
Additionally, growth factors may be characterized as either progression or competency 
growth factors depending on how they affect gene expression (9, p. 2). Progression growth 
factors are those that "stimulate genes as a result of transit through the cell cycle (9, p. 2)." That 
is, they simply keep the cell cycle moving, resulting in continual, uninterrupted mitogenesis. 
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Competency growth factors, on the other hand, are those that express genes that ultimately 
cause cells to be kicked out of their dormant GO stage and into the Gl and through the S phase 
(9, p. 2). Another characteristic of competency growth factors is that they function even in the 
presence of a protein inhibitor like cycloheximide because they require no protein synthesis to 
transcribe "early-intermediate response" genes (6). Protein synthesis is required in the recipi-
ent cell, however, in order to activate secondary or "delayed response" genes (6). Both PDGF 
and bFGF are competency factors. 
Overview of bFGF : discovery and specific actions 
The FGF family consists of seven related polypeptides of which basic FGF and acidic FGF are 
the best characterized. bFGF was not identified until the mid 1970s (3, p. xi). Labeled first as a 
mitogen, bFGF has been found to produce cell proliferation in a variety of cell types from mes-
enchymal to neuroectodermal (10, p. 161). Figure 1 (11, p. 293) shows that exposure to bFGF 
causes a significant increase in arterial endothelial cell replication. Some of bFGF's activities 
related to its mitogenic properties include an increase in the survival of cells packed 
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at clonal density, the prevention of death when cells are exposed to a stressful environment (a 
serum-free medium), and the general increase in the life span of cultured cells (12, p. 2). Per-
haps bFGF's most distinguishing in vivo activity is its stimulation of angiogenesis, or the pro-
duction of new blood vessels. Experiments with bFGF showed for the first time that a growth 
factor could be both a mitogen and a morphogen (12, p. 2). In vitro experiments have indicated 
that bFGF elicits signals in the early developing Xenopus embryo which stimulates the forma-
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tion of mesoderm. bFGF's ability to reorganize the extracellular matrix by inhibiting collagen 
type I and fibronectin with various proteases and collagenases, and promoting collagen type IT 
synthesis explains its capability to differentiate cell lines such as vascular endothelial cells and 
chondrocytes (12, p. 3). To summarize, bFGF's in vivo roles include mitogenesis, cell differen-
tiation, embryonic development/mesoderm formation, and angiogenesis. In general, bFGF 
functions in the maintenance and survival of certain tissues (3, p. xi). 
The bFGF gene includes two introns (16kbs each) and three exons (36kbs total) (13, p. 
109). Following transcription of the gene, the mRNA is translated into a polypeptide about 154 
amino acids long (14, p. 157) that encodes a complex of four isoforms (13, p. 114). The three 
largest isoforms are initiated unconventionally by the leucine codon (CUG) while the smaller 
isoform is initiated by the usual methionine "start" codon (AUG). This unusual translation is 
unique for bFGF and does not occur with other competency factors (15, p. 204). The recent dis-
covery of this anomaly could mean that some activities previously attributed to the known 
smaller isoform could actually be functions of one or more of the larger isoforms. The differ-
ences in weight could also be a possible mechanism for post-translational regulation of expres-
sion, function, or localization of bFGF (13, p. 114). Until recently, it was thought that since two 
cysteine residues are conserved in all FGF family members, they must form a disulfide bond, 
which would also have an impact on bFGF's structure/ function relationship. X-ray crystallog-
raphy has confirmed, however, that no disulfide bond exists (16, p. 107). 
Secretory signal sequence, localization, and release of bFGF 
In general, growth factors are synthesized only when needed and not stored anywhere, but 
bFGF may be a partial exception to this rule (7). Since bFGF is the only member of its family 
not to have a known signal sequence for secretion, it was thought that bFGF was only released 
from dead or dying cells as part of the inflammatory response during wound healing (7). 
However, new lines of evidence suggest that there must, indeed, be a signal sequence for se-
cretion. If one living cell is isolated and cultured, bFGF is released from the cell without the 
occurrence of injury (15, p. 206). Also, the differences in weight of the bFGF isoforms is shown 
to have a role in its localization and release. The N-terminal amino acid sequence of the 
heavier isoforms is called the "nuclear targeting sequence" and determines that they will be 
localized to the nucleus (15, p. 205). The lighter isoform, however, is localized to the cyto-
plasm and exported to the surface (13, p. 118). This difference in localization also suggests a 
difference in function. The heavier isoforms are implicated in an autocrine mitogenic action 
since they are localized to the nucleus, and the lighter isoform in a paracrine action since it is 
exported. It is known that endogenous bFGF is not enough to cause the cell to proliferate, so 
exogenous bFGF must be taken up (17, p. 132). 
Since there is no evidence for the traditional pathway of secretion, which includes pack-
aging by the endoplasmic reticulum and Golgi apparatus, and finally exocytosis across the 
membrane, a non-traditional pathway must exist. One suggestion is that bFGF binds to hep-
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arin sulfate in the cytoplasm, and is transported to the membrane (18, p. 207). Another differ-
ence between bFGF and other growth factors is that it is not released in a soluble form, but is 
thought to become an integral part of the extracellular matrix once it is transported across the 
membrane. In the matrix, bFGF binds with high affinity to heparin sulfate proteoglycans 
(HSPGs), which serve to protect the growth factor from degradation, to keep the growth factor 
localized, and to keep bFGF from continually acting on itself (12, p. 4). bFGF is stored within 
basement membranes and in the matrix and is normally sequestered in emergencies (18, p. 
208). Evidence for this kind of release is substantial. bFGF is known to be released from the 
extracellular matrix by heparanases (platelets, macrophages, neutrophils, or lymphocytes-
cells of the immune system) which are also elicited in response to wound healing (18, p. 212). 
Additionally, the hydrolysis of the extracellular matrix produces active heparin/bFGF com-
plexes. Moreover, where hydrolysis occurs in vivo, there is a corresponding increase in mitoge-
nic activity (12, p. 5). 
Receptor and signal transduction for bFGF 
Two types of receptors, low and high affinity, have been described for bFGF. As previously 
discussed, once bFGF has crossed the membrane into the extracellular matrix, it binds to 
HSPGs. These heparin-like structures, which are generated by plasmin and indirectly activated 
by bFGF itself (19, p. 180), may also exist on the cell-surface. They exist as low affinity recep-
tors, but do not function in transducing the bFGF signal. The HSPGs bind bFGF and induce a 
conformational change so that it has even higher affinity for the primary receptors (16, p. 99). 
Although the affinity for HSPGs in the extracellular matrix is relatively high and the abun-
dance of HSPGs is much greater than the abundance of primary receptors, the affinity for the 
primary receptors is two to three times stronger (19, p. 177). The cell-associated HSPGs also act 
as a buffer by slowly releasing bFGF to its receptors over a period of time. Thus the bFGF is 
efficiently transported to its high-affinity receptor, and long-term responses can be elicited 
from a short burst of bFGF (19, p. 179). HSPGs also protect bFGF from degradation by pro-
teases including trypsin and chymotrypsin (19, p. 179). 
X-ray crystallography has generated a great deal of information about the structure of 
bFGF and its binding domains to both the receptor and the heparin substrate. The sequence of 
amino acids 115-124 is implicated in receptor binding because it lies on the surface of the pro-
tein and contains a Threonine-121, which is shown to enhance bFGF's affinity for the receptor 
when phosphorylated by protein kinase A, probably by inducing a conformational change (16, 
p. 99). Important residues for high biological activity of the heparin binding to bFGF are stabi-
lized by noncovalent interactions at both the carboxy (C) and amino (N) terminal sequences 
(16, p. 106). There is also some evidence that heparin and the receptor might share binding site 
domains, but an intact 3-D structure seems to be more important to binding than actual bind-
ing domains. 
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Three high-affinity bFGF receptors, which do function in transducing the signal, have 
been isolated and described based on their possession of tyrosine kinase (T -K) domains. They 
are the fms-like gene (fig), the bacterially expressed kinase (bek), and the chicken embryo ki-
nase (CEK-2) (10, p. 161). T-K receptors are characteristic of all competency factors (15, p. 204). 
Although bFGF binds to a receptor with T-K activity as PDGF does, its signal transduction 
mechanism is not identical and is not well understood. 
It is thought to be similar to PDGF's mechanism in that it activates the phosphatidyl-
inositol pathway, which is known to have an integral part in cell proliferation, but unique in 
that it activates the pathway at different points (7). Unlike the PDGF pathway, proliferation 
still occurs when the phosphatidylinositol pathway is blocked, indicating the presence of an 
additional mechanism (7). The pleiotropic actions of bFGF are known to be primarily regulated 
by the protein tyrosine kinase that is intrinsic in all of FGF receptors (20, p. 147). However, 
bFGF's mitogenic effects are much more efficient in combination with G-protein activating 
agents, like thrombin (20, p. 146). It has been demonstrated that hormones or neurotransmit-
ters that are known to use the G-protein pathway to transduce their signals also function as 
mitogenic inhibitors or stimulators (21, p. 90). The application of Pertussis toxin, which is 
known to uncouple the G-protein pathway, succeeded in blocking hormone or neurotransmit-
ter produced proliferation, but had no effect on growth factor mitogenesis (21, p. 91). These 
two lines of experiments with the phosphatidylinositol pathway and G-protein coupled path-
ways indicates the possibility of the existence of two independent mechanisms for bFGF signal 
transduction leading to cell proliferation. 
Overview of POGF: discovery and specific actions 
In 1955, it was discovered that no animal cells could survive without a minimum amount of 
animal protein like blood serum (9, p. 3). Fibroblast cells that were deprived of the serum en-
tered the GO latent stage, but if they were restimulated with serum, they entered the G1 phase 
and proceeded through the cell cycle. The fact that the change induced in the fibroblast cells 
continued to be detectable even after the serum was removed and that the cells were commit-
ted to the change even after a brief exposure was sufficient evidence to speculate that there 
was some macromolecule in serum that induced the change (9, p. 3). It was not until 1977, 
however, that researchers discovered that the removal of platelets from the serum suspended 
cell proliferation (9, p. 4). This breakthrough quickly led to the isolation of the growth-induc-
ing factor, PDGF, from platelets. 
Similar to bFGF, functions of PDGF include proliferation, chemotaxis, matrix produc-
tion, and an integral part in the wound healing process (22, p. 41). PDGF has also recently been 
found in the human placenta and in the Xenopus embryo which suggests a role in embryonic 
development and differentiation as well (22, p. 41). Sources of PDGF include platelets, endo-
thelial cells in blood vessels, and macrophages (23, p. 1564). 
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PDGF is a 30 kDa disulfide-bonded dimer of two chains, A and B, which show 60% ho-
mology (22, p. 42). Combinations of these two chains can give AA, AB, and BB isoforms of 
PDGF, all of which have been reproduced synthetically (24, p. 328). 
Secretory signal sequence, localization and release of PDGF 
The synthesis and release of PDGF is well documented and generally understood to occur via 
the normal pathway. That is, PDGF is not synthesized until it is needed, not stored anywhere 
within the cell or the matrix, and is packaged for secretion by the endoplasmic reticulum and 
the Golgi apparatus directly after synthesis. Like the isoforms of bFGF, the presence of mul-
tiple isoforms of PDGF implies that they, too, might have differences in function. Indeed, there 
is an exception to the secretory pattern just described. AA and AB isoforms are processed via 
the normal pathway and secreted right after synthesis, suggesting a paracrine function (22, p. 
42). Isoform BB, however, stays associated with the producer cell, which implies an autocrine 
function (22, p. 42). 
Receptors and signal transduction for PDGF 
Although the signal transduction through the PDGF receptor is a relatively well described sys-
tem, its mechanism still has not been completely elucidated. Like the ligand, the PDGF recep-
tor also has two similar but distinct subunits, alpha and beta. Three dimeric receptor types, 
each with specific ligand binding affinities, can be formed by the combinations of the two sub-
units. The alpha-alpha receptor type can bind any of the three isoforms of PDGF while the al-
pha-beta receptor can only bind AB and BB forms and the beta-beta receptor can only bind the 
BB form of PDGF (24, p. 336). 
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The PDGF receptor is a 180-190 kDa glycoprotein and can be found in the membranes 
of vascular smooth muscle cells, fibroblasts, and glial cells (23, p. 1564). Figure 2 (23, p. 1565) 
shows the organization of the PDGF receptor. The most characteristic aspect of the receptor is 
its tyrosine kinase domain. A unique part of the receptor is the tyrosine-kinase insert which 
interrupts the T-K domain. Since many growth factors do not have a tyrosine kinase insert do-
main, it had been suggested that perhaps it did not have a significant role in cell proliferation. 
However, further studies showed that the removal of the insert produced a "blunted mitoge-
nic response (23, p. 1569)." There are also five extracellular immunoglobulin-like domains (D1-
D5) (23, p. 1565). Evidence for their existence is the presence of five regular repeats in the 
amino acid sequence, characteristic disulfide bonds, a similarity to sequences of known immu-
noglobulin domains, and a capacity for recognition (23, p. 1566). The N terminus of the recep-
tor is extracellular and the C terminus is intracellular. There is also one hydrophobic sequence 
of amino acids that forms the transmembrane sequence. Although its activity is not precisely 
known, it does serve more than just an anchor in the membrane. Replacement of the sequence 
with another transmembrane receptor sequence does not affect binding affinity, but fails to 
propagate the signal to the intercellular T -K domain (23, p. 1566). Since the AA isoform of 
PDGF does not stimulate chemotaxis whereas the AB and BB forms do, a difference between 
the alpha-alpha receptor and the other two is suggested (7,43). Indeed, when compared, there 
is only a 30% homology in the extracellular domain, an 80% homology at the kinase domain, 
and a 30% homology at the kinase insert and carboxy terminus (22, p. 43). 
As shown by Wilson in figure 3 (23, p. 1567), there are four possible models for PDGF 
signal transduction. The first model suggests that a conformational change is induced in the 
receptor by the agitation of the transmembrane portion. The second mechanism involves the 
perpendicular movement of the receptor to the membrane. The third mechanism is that PDGF 
binding may induce a receptor dimer that could result in the formation of a cytoplasmic active 
site for a T-K substrate. In the fourth model the receptor is already in the form of a dimer and 
PDGF binding induces conformational changes (23, p. 1567). The dimeric models are the most 
plausible since they can account for the specificity and conservation of the transmembrane 
portions (23, p. 1567). 
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When PDGF binds to its receptor, a number of responses are elicited, such as activation 
of the T -K domain which proceeds to activate several other intracellular pathways, conforma-
tional change due to autophosphorylation, increased expression of secondary genes, change in 
ion fluxes, modulation of cellular pH, increase in calcium concentration, elevation of cAMP, 
and the downregulation of the receptor (23, p. 1568). It is possible that each of these events 
does not activate some independent pathway, but may all act together to provide a better envi-
ronment for more efficient signal transduction (25, p. 120), replication of the DNA, and divi-
sion of the cell (23, p. 1564). 
It has been suggested that the T-K domain may act as a "switch kinase" that would inte-
grate the various stimuli and relay the signal in a pleiotropic response (21, p. 87). The activa-
tion of the T-K domain is indeed critical to the transduction of the signal because it activates a 
number of other pathways, such as the phosphatidylinositol pathway, by phosphorylation that 
are known to stimulate mitogenesis. Mitogenesis due to the actions of PDGF is known to be 
inhibited when the phosphatidylinositol pathway is blocked (7). Autophosphorylation, or 
phosphorylation by a neighboring catalytic domain, of the T -K intrinsic enzyme increases the 
Vmax of the kinase, which enables the receptor to maintain a high level of activity even in the 
absence of the growth factor (26, p. 68). Although specific T -K substrates have not been identi-
fied, studies of inactivation of the T-K domain show that it is responsible for the activation of 
all the responses to PDGF binding except downregulation (23, p. 1568). This activity is appar-
ently controlled by the insert domain (23, p. 1568). Downregulation is when the cell becomes 
less sensitive to the growth factor binding because of the degradation of previously bound re-
ceptors (6). The rate of PDGF receptor turnover is relatively high and it is not recycled back to 
the surface of the membrane (22, p. 43). Therefore, response to PDGF relies on the growth 
factor's concentration as well as the expression of the receptor. Additionally, the characteristic 
secondary or delayed response genes produced as a result of PDGF binding have been identi-
fied as mediators of the signal sequence. C-myc is a nuclear-binding protein and may be active 
as a transcriptional promoter or activator of DNA synthesis itself (9, p. 18). C-fos is a nuclear 
phosphoprotein involved in transcription regulation and c-jun is an important transcription 
factor (9, p. 18). 
What happens after the signal is transduced? 
After signal transduction takes place, most receptor-growth factor complexes are known to be 
taken into the cell via endocytosis and degraded by lysosomes. This is the process that contrib-
utes to downregulation. Some receptors like the insulin receptor are transported back to the 
membrane surface after endocytosis and reused. There is also recent controversial evidence 
that bFGF is taken into the cell via endocytosis as before, but is then translocated directly to the 
nucleus (6). The mechanism is unclear, but there is a close relationship between an increase in 
the amount of bFGF in the nucleus and the onset of the S phase of the cell cycle when DNA is 
replicated (17, p. 132). 
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CLINICAL APPLICATIONS IN WOUND REPAIR 
A handful of growth factors, including bFGF and PDGF, are present in the wound environ-
ment (27, p. 359). Here they are known to be essential in just about every aspect of the normal 
wound healing process including the restoration of blood flow, tissue strength, and a barrier to 
infection (28, p. 306). The normal wound healing process can be divided into three distinct 
stages. 
The first stage in the process of wound healing is characterized by inflammation and 
hemostasis. A wound usually results in hemorrhaging, which is the disruption of the vascular 
supply. In response, platelets are mobilized to the wound site, resulting in the release of 
growth factors, thromboplastin, and the formation of a clot (29, p. 341). The second stage of 
wound healing occurs when macrophages, and fibroblasts, stimulated by growth factors, mi-
grate to the wound site to form granulation tissue and a new layer of epithelialization (29, p. 
341). The final stage of the healing process is characterized by the remodeling of the newly 
synthesized granulation tissue and the matrix. This process, which serves to increase the 
strength of the tissue, is brought about by the increase in the amount of collagen type I in the 
extracellular matrix (29, p. 341). 
Since growth factors have been shown to be an integral part of the wound healing pro-
cess, perhaps the application of synthetic growth factors could help heal chronic wounds or 
even speed up the process of normal wound healing. Only in the last decade, however, has 
there been sufficient biochemical characterization of growth factors and their activities to pro-
ceed with the application of recombinant growth factor products to the wound healing process 
(28, p. 306). 
Studies of bFGF's potential for clinical application 
bFGF was one of the first growth factors to be evaluated as a potential synthetic product, be-
cause of its known mitogenic and angiogenic properties, both of which are extremely impor-
tant in the wound healing process. The advent of Synergen's acquisition of a patent for 
recombinant bFGF led to a dramatic increase in the number of in vivo wound healing experi-
ments. 
One such experiment, as demonstrated by Broadley and Davidson (28, pp. 306-315), 
involved wound healing in normal juvenile rats. Three wound models were used, each provid-
ing different quantitative measurements of the healing process. The first model involves 
wounds that are produced by subcutaneous implants of alcohol sponges. This wound model 
measures the increase in the cellularity of newly synthesized granulation tissue by comparing 
relative content of collagen (by amount of hydroxyproline), DNA, and protein. In the second 
wound model, transcutaneous, longitudinal, incisional wounds are made on the backs of the 
rats and closed by wound clips. The third model involves a transecting wound through the 
median collateral ligament of the hind limb. Both the second and third models measured such 
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tensile properties of wound healing as breaking energy and strength. bFGF was administered 
on the third day after wounds were made to allow the inflammatory response to subside. Ad-
ditionally, each wound was examined histologically to insure that mitogenesis and 
angiogenesis were indeed occurring. 
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The results of the experiments were encouraging. Figure 4 (28, p. 308) shows the quanti-
tative measurements of wound healing for the sponge implant wound model. Panel A shows 
the classic mitogenic effect of bFGF, which is its ability to stimulate the replication of DNA. 
Panel B also shows that bFGF stimulates an increase in protein. Panels C and D show that 
there was a decrease in the amount of collagen. This is indicative of bFGF's collagenase 
activity. 
Figure 5 (28, p. 310) compares the results of continuous slow release (1.0 micrograms 
per day) versus acute dosing in the subcutaneous sponge implant model. Although both 
modes of presentation showed increased granulation and vascularization when compared to 
the untreated wound, continuous release was shown to produce a much larger angiogenic and 
mitogenic response than the acute dosage. These findings suggest that the mode of presenta-
tion of the growth factor plays a large role in the wound-model healing responses (28, p. 309). 
Figure 6 (28, p. 311) illustrates the effects of continuous release of bFGF on the 
transecting ligament wound model. The treated model showed a marked increase in granula-
tion tissue when compared to the untreated model, but showed no difference in tensile 
strength. These results are also indicative of bFGF's collagenase activity. 
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Figure 5 
Figure 6 
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bFGF and chronic wound healing 
The study ofbFGF's impact on the repair process in impaired-healing wound models is much 
more important for a number of reasons. First, normal healing is usually fairly efficient, and 
not problematic. Growth factors might not accelerate the normal process significantly anyway. 
Secondly, the most problematic wounds, both clinically and financially, are chronic wounds 
that are already impaired by things like diabetes, administration of glucocorticoids, exposure 
to chemotherapeutic substances, or simply old age (28, p. 307). It is the healing of these 
wounds which would have the most to gain from growth factor research. 
In an experiment demonstrated by Fiddes et al. (30, pp. 321-328), diabetic mice were 
used to determine the effects of bFGF on healing-impaired wounds models. Healing rates in 
diabetic mice are impaired by 35-50% that of a normal mouse (3D, p. 321). The mice were either 
genetically bred to have diabetes or were injected with streptozotocin, which induces diabetes. 
Diabetic mice were shown to exhibit many of the same symptoms that diabetic humans do, 
including hyperglycemia, obesity, and hyperinsulemia (3D, p. 328). 
For the experiment, full-thickness wounds, through the epidermis, dermis and the 
panniculus camosus muscle, were made on the flank of each diabetic (db/db) mouse. The 
bFGF and control solutions were then administered topically to the wounds in 20 microliter 
acute doses. Healing was measured by contraction, granulization, and epithelialization at the 
wound site (3D, p. 321). 
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Figure 7 
The results, as shown in figure 7, indicate that the time required for a 50% reduction in 
wound area was improved from 18 days without bFGF to eight days with bFGF (3~, p. 323). 
The graph also shows a much more significant increase in the healing rate of the bFGF-treated 
diabetic mice than for the bFGF-treated non-diabetic mice. This is evidence that bFGF may be 
more effective in the clinical setting as a factor to help chronic wound healing, but may not be 
significantly effective in accelerating the normal wound-healing process. Figure 8 more clearly 
illustrates that bFGF is effective to help heal diabetic wounds in mice, showing that a diabetic 
wound treated with bFGF was practically closed by day 12 whereas the untreated wound 
showed little change (3D, p. 324). 
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Figure 8 
Also studied were the effects of bFGF on bacterial or fungal infection of wounds. This 
type of study is important because of the recent discovery that topical administration of anti-
microbial agents that were previously used to fight infection are now known to be cytotoxic 
(3D, p. 323). Perhaps there is the possibility that bFGF could be used as an alternative therapy. 
Full-thickness burns were made in the backs of anesthetized rats by placing them into boiling 
water. The burns were then infected with E. Coli bacteria, both acutely and chronically. A dose 
as small as 1.0 microgram bFGF / cm "2 did improve wound healing in rats that were acutely 
infected with bacteria. However, chronically infected wounds required a dose of 100 micro-
grams bFGF / cm"2 to improve healing significantly (3~, p. 325). This type of information from 
various experiments could form the basis of dosage recommendations for the clinical applica-
tions of growth factors to different wound types (3D, p. 327). 
Steroid-impaired models, produced by glucocorticoid injections, showed a 40% de-
crease in wound healing rate over 12 days. This decrease in the healing rate is due to the inhi-
bition of the inflammatory response. It is important to note that treatment with bFGF was able 
to restore the normal healing rate (31, p. 452). 
PDGF and chronic wound healing 
PDGF's particular role in the healing process includes the stimulation of compounds like 
fibronectin, glycosaminoglycan, and collagenase, which are all essential to tissue repair be-
cause of their role in the remodeling of the extracellular matrix (27, p. 361). As with bFGF, ex-
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periments were done to determine PDGF's effect on the normal healing rate, and similar re-
sults were produced. Again, the most important studies were those done on healing-impaired 
rats. 
Of the PDGF isoforms, AA and BB are the best described with respect to their clinical 
application. Similarities in function, structure, and experimental results may be explained by 
the fact that both are able to bind to the same receptor type (24, p. 336). In similar experiments 
with diabetic mice, treatment of wounds with both the AA and BB isoforms of PDGF also re-
sulted in a thickened layer of granulation tissue, capillaries, and fibroblasts (24, p. 334). Treat-
ment of gastrointestinal wounds in mice with PDGF only resulted in an increase in cellularity 
and migration of macrophages, neutrophils, and fibroblasts at the wound site, but no corre-
sponding increase in wound strength (27, p. 368). These findings are also consistent with 
PDGF action since it is known to stimulate collagenases. 
A study which identifies one of the differences between bFGF and PDGF action in-
volves the treatment of full-thickness wounds with glucocorticoid steroids, which serves to 
eliminate fibroblasts and macrophages from the wound area. Remember that treatment of this 
type of wound with bFGF returns the wound's normal healing rate. However, treatment with 
PDGF shows no effective increase in healing (27, p. 362). Unlike the bFGF mechanism, it is 
thought that macrophages are essential as a source of PDGF and for the initiation of the signal 
sequence that touches off a cascade of events culminating in cell proliferation. 
Growth factors and fracture healing 
Growth factors have been found to playa key role in the fracture healing process as well. This 
mechanism, if anything, is more complex than the previously discussed wound repair mecha-
nism in two important ways. First, bone heals by regeneration, not by scarring. Secondly, frac-
ture healing involves the differentiation of osteoblasts and chondrocytes as well as fibroblasts 
(32, p. 391). bFGF and PDGF are both implicated in the fracture healing process, but are deliv-
ered to the site in different ways. PDGF is delivered via platelets in the blood stream, whereas 
bFGf is delivered through local expression at the fracture site (32, p. 393). Experiments with 
bilateral fractures of a rat femur provide evidence of growth factor activity. PDGF is shown to 
appear at the wound site first to stimulate mitogenesis in mesenchymal cells and to regulate 
the formation of intramembranous bone (32, p. 410). bFGF was shown to be present at the en-
dochondral ossification site because of its known stimulation of collagenase activity, 
angiogenesis, and mitogenesis of chondrocytes and osteoblasts (32, p. 410). Further studies in 
the roles of growth factors could lead to new therapies in fracture healing. 
GROWTH FACTOR'S IMPLICATION IN PATHOLOGY 
In general, growth factors are clearly beneficial compounds. They are associated with many 
vital physiological processes including an integral role in wound healing. Ironically, a slight 
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disruption of the growth factor system may also lead to disaster for an organism. There are 
several examples where there exists a fine balance between the beneficial adaptation of the 
growth factor mechanism and the initiation of pathology. 
One such example deals with neuronal regeneration in the brain. When bFGF is added 
to hippocampal cells it is known to increase neuronal survival in vitro and in vivo (33, p. 221). 
By using a monoclonal antibody that specifically recognizes bFGF conformation, it was deter-
mined that there is a high concentration of bFGF in CA2 neurons in the hippocampus as 
shown in figure 9 (33, p. 223). This region is also known to be the most resistant to aging and 
epilepsy indicating that bFGF may contribute to this property (33, p. 222). Alzheimer's Disease 
Figure 9 
(AD) is a progressive degenerative disease in select brain areas including the entorhinal cor-
tex, which is the main input to the hippocampus and often the first affected. Where neurons 
first begin to degenerate, bFGF is released in an attempt to sprout new axons to compensate 
for the loss of connections (33, p. 224). A hallmark of AD is the presence of "senile plaques" 
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which are deposits of amyloid which appear to form along the border of degenerated areas 
and neuronal sprouting. The corrlbination of high concentration of bFGF and heparin sulfate 
may cause the misdirection of sprouting into plaque formation (33, p. 226). Although bFGF 
initially acts to promote growth and slow degeneration of neurons, it may also lead to the pro-
gression of AD if the system is disrupted slightly (33, p. 229). 
Huntington's Disease is caused when brain tissue fails to generate enough energy to 
function. High lactic acid concentrations in the brains of Huntington's patients indicate that 
their mitochondria are not functioning. (34, p. 292). It was also discovered that there are fewer 
bFGF receptors in brain cells of Huntington's patients than in normal patients. Since bFGF is 
known to assist neurons in coping with high energy requirements (34, p. 292), the lack of the 
normal number of bFGF receptors in conjunction with malfunctioning mitochondria is espe-
cially dangerous. 
PDGF actions also have a pathog~nic side and have been tied to fibrosis and atheroscle-
rosis (22, p. 41). Its activity in the initiation of atherosclerosis is perhaps the most significant 
example since atherosclerosis may then lead to myocardial and cerebral infarction (35, p. 195). 
The process is initiated when endothelial cells of the arteries become dysfunctional or injured 
by things like high cholesterol level, or hypertension (35, p. 195). Injury to the endothelial cells 
stimulates the attachment of platelets and macrophages and the subsequent secretion of PDGF 
in an attempt to heal the injury. This causes a cascade of smooth muscle cell proliferation. 
Eventually the build-up of cells becomes big enough to block the artery and may lead to 
infarction. Recently, it has been confirmed that PDGF is indeed localized within atherosclerotic 
lesions (35, p. 196). The same process of injury and subsequent increase in PDGF and macroph-
ages, also occurs within the lungs, leading to pulmonary fibrosis (35, p. 197). 
Growth factors also have an undeniable link to cancer. In fact, some oncogenes have 
been found to have 40-500/0 homology to bFGF genes (3, p. xi). As mentioned before, some 
growth factors are only known by their oncogenes. Additionally, more oncogenes are pro-
duced as a result of a mutation of the growth factor receptor or compounds associated with 
growth factor regulation than of the growth factor itself (6). There is evidence that excessive 
synthesis of, or the production of an altered version of a growth factor or receptor has a trans-
forming effect on recipient cells (4, p. 1159). Cells that are elicited in response to a wound 
(macrophages, neutrophils, and lymphocytes) might also be attracted to a tumor and may in-
directly stimulate angiogenesis of tumor by way of their heparanase activity (18, p. 212). The 
expression of a normally dormant growth factor gene may also lead to cancer. For example, 
bFGF is a mitogen for melanocytes, but unlike other cells that react to bFGF, a melanocyte does 
not produce its own bFGF. The bFGF gene in normal melanocytes is suppressed whereas in 
malignant melanomas, it is activated (36, p. 233). At the same time, cells that have been dam-
aged by radiation secrete bFGF and are able to repair potentially carcinogenic damage (18, p. 
219). 
Although growth factor receptors are essential for the transduction of the growth factor 
signal to the recipient cell, it is also not uncommon for them to be used as portals of entry for 
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viruses. For instance, the rabies virus is known to enter the cell through acetylcholine receptors 
(37, p. 1410). There is also strong evidence that the bFGF receptor is used as a portal of entry 
for the herpes simplex virus type I (HSV I) (37, p. 1410). Inhibitors of bFGF binding and com-
petitive compounds both prevented HSV I uptake. Additionally, some cells lacking the bFGF 
receptor are known to be resistant to the virus (37, p. 1410). 
Although in vivo experiments have indicated that growth factors prevent retina degen-
eration and help heal damaged corneas (3, p. xii), the clinical application of growth factors in 
eye drops has been problematic because it resulted in the thickening of the cornea (7). 
bFGF mRNAs have also been found to be expressed in high levels from cells of Kaposi's 
sarcoma lesions which are associated with infection by the HIV virus (38, p. 223). 
SOCIETAL ISSUES 
Economic considerations 
Growth factors play an important role in the acceleration of the wound healing process, the 
healing of chronic wounds, and could also be involved in new therapies for incurable patholo-
gies. Thus, the need for the production of synthetic growth factors is evident. Since wounds 
are as common as the cold and new therapies for existing diseases are always needed, there is 
also a huge market for synthetic growth factors. A synthetic growth factor, effective in acceler-
ating the chronic wound healing process, would comer much of the wound care market, for 
which up to four billion dollars is spent annually in the United States alone (1, p. 1065). 
The huge market, immense need, and especially the opportunity for financial gain is 
producing needed cutting-edge research in the areas of growth factor mechanism and syn-
thetic production. Biotechnology companies like Genentech, Amgen, Synergen, Zymogen, and 
pharmaceutical firms like Merck are all in competition to produce synthetic forms of growth 
factors (39, p. 141). As of December 1991, however, only Synergen had been granted a patent 
for recombinant bFGF and is currently seeking market approval from the FDA (39, p. 141). The 
recombinant human basic FGF (rh-bFGF) is produced by the plasmid pFC81 which carries the 
bFGF gene into E. Coli for expression (40, p. 330). It is difficult, however, to convince both sci-
entists and FDA officials of a particular growth factor's therapeutic advantage because its ef-
fectiveness is not easily quantified. For instance, increasing the oxygen supply, using 
water-absorbing bandages, or simply cleaning will improve healing of a damaged area (39, p. 
141). To prove that the growth factor accelerates the process even further is difficult. 
Ethical issues 
Since steroids and growth hormone are also, in a sense, growth factors, one has to ask if either 
bFGF or PDGF could also be used in potentially dangerous and unethical ways. Could syn-
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thetic growth factors get out of hand? Probably not. Since skeletal muscle cells enlarge instead 
of replicating, and bFGF and PDGF are both mitogens, they could not act to increase skeletal 
muscle mass. It would also be difficult to increase the entire body size with bFGF and PDGF 
since their actions are paracrine and autocrine. In order to get a general effect, one would have 
to apply the growth factors through the blood stream. They would also have to be applied in 
high doses because the majority would be degraded in the liver. High doses could have poten-
tially dangerous side effects such as unregulated cell growth. However, the growth would 
probably be localized and non-malignant (6). 
The ethical considerations of patenting should also be considered. Should we be al-
lowed to patent synthetic growth factors? After all, growth factors are a natural part of the hu-
man body. Is it ethical to patent parts of ourselves? If so, where does it stop? For instance, who 
is going to own the patent for the life process itself? There have already been reports of obvi-
ous misuse of the patent system. In particular, one scientist requested patents on peptide se-
quences discovered in the brain without even knowing their function! James Watson, of 
Watson and Crick fame, was so opposed to the random patenting of sequences, that he lost his 
job with the human genome project (6). After all, once a patent for a particular growth factor 
has been received, rival labs could request a patent on a new growth factor with a similar func-
tion simply by altering a single amino acid. Conversely, if patents on growth factors were not 
permitted, perhaps it would decrease the initiative to produce these potentially beneficial 
products 
FUTURE OUTLOOK 
One would think that the combination of "cutting-edge research, a crying medical need, and a 
huge market" would be a "surefire prescription for success (1, p. 1065)." Results, however, 
have been disappointing mainly because researchers are trying to find a single "cure-all" 
growth factor (1, p. 1065). Since there are an enormous number of known growth factors in 
tissues, it has been extremely difficult to determine which ones are most crucial to wound re-
pair and which ones are essential to the developmental process. There are a number of areas to 
which growth factor research might be directed in the future. 
The use of growth factor synergism, or the interaction of two or more growth factors, 
has shown promise and is definitely more representative of what happens in vivo (28, p. 313). 
A veritable cocktail of growth factors which act in different ways might produce a more desir-
able clinical effect. For instance, the experiments discussed showed that bFGF and PDGF both 
increased granulation tissue but because of their collagenase activities did not increase col-
lagen content or tensile strength of the healed wound. The activation of transforming growth 
factor (TGF) is necessary to induce collagen type I synthesis. Therefore, a suggestion might be 
to give PDGF to recruit infection-fighting cells, bFGF to promote vascularization, and TGF to 
help deposit and strengthen the matrix. 
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Also, the type of growth factor that is used in clinical situations should depend upon 
the type of wound (39, p. 141). For instance, wounds that have circulation disorders like dia-
betic or venous ulcers and pressure sores might be most efficiently treated with bFGF because 
of its known promotion of angiogenesis. 
Improving the quality and not just the speed of the wound healing process is another 
interesting area of research for the future. This might involve the study of wound healing in 
fetuses. Children that had been operated on as 18 to 28 week old fetuses have shown no trace 
of a scar upon birth (1, p. 1066). Histologically, wounds that are repaired fetally and normal 
skin are practically indistinguishable (1, p. 1066). Perhaps the study of the factors associated 
with fetal wound healing could lead to the ability to heal wounds without a scar. This would 
have a major aesthetic impact as well as alleviating many of the problems associated with scar 
tissue. 
Moreover, future research might be directed towards the production of growth factor 
"antagonists" which could be beneficial where the stimulation of growth factors was uncon-
trolled (1, p. 1065). 
SUMMARY 
Perhaps one of the most important aspect of growth factors is their role in the wound healing 
process. Experiments have shown that synthetic growth factors play an essential role in the 
healing of chronic wounds and the acceleration of the normal healing process. Although 
growth factors are known to be associated with vital physiological processes like mitogenesis, 
embryonic development, angiogenesis, and neuron regeneration, they are also implicated in 
potentially lethal pathologies like Alzheimer's Disease, melanomas, and atherosclerosis. The 
potential for clinical applications of growth factors and the huge market for such a product has 
produced intense research and competition among biotechnology companies to corner the 
market on synthetic growth factors. In conclusion, it is important to realize that a major part of 
the growth factor mechanism and methods of interaction with both the producing and recipi-
ent cells is still unknown. A vast amount of research still remains to be done in order to clarify 
the growth factor's possible impact on clinical application. An appropriate statement is that, 
"If you aren't confused, you simply don't understand what's going on here (8, p. 228)." 
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ADDENDUM 
Introduction 
The FGF family consists of seven related polypeptides of which bFGF is one of the best 
characterized. Some of bFGF's in vivo functions include mitogenesis of a wide variety of 
cell types, chemotaxis, cell differentiation, and angiogenesis. These properties have made 
bFGF valuable as a synthetic product for clinical applications in chronic wound healing, 
accelerating the normal healing process, and perhaps even as a new therapy for diseases 
like Alzheimer's disease or atherosclerosis. Although bFGF is primarily a mitogen, it is 
also functions to increase the life span of cultured cells, and to prevent the death of cells 
that are exposed to a serum-free medium. Through experiments with cultured, non-
transformed 3T3 mouse cells, I hope to show how long it takes bFGF to retrieve cells from 
death, and to suggest a possible mechanism for such a retrievaL 
Materials and Methods 
Non-transformed mouse 3T3 fibroblast cells were cultured in a medium with 10% calf-
serum and exposed to radioactive Chromium 51 (Cr 51). After six hours, the cells were 
rinsed with serum-free medium. Half of the cultures were then exposed to a serum-free 
medium with bFGF while the control cultures were exposed only to serum-free medium. 
At 5, 10, and 15 hours, all cultures were assayed with a scintillation counter for the percent 
chromium released. 
Results and Discussion 
Although Cr 51 may also slowly leak out of the cells in both the control and bFGF-treated 
cultures, the percent Cr 51 released is generally a measure of cell death. The experiment 
was reproduced nine times and the average percent releases, as shown in the table and 
graph, indicate that a significant difference between the survival of the control and the 
bFGF-treated cultures occurs between 5 and 10 hours. Since bFGF is known to produce cell 
proliferation only after a 10-12 hour lag period, the signal transduction for the retrieval of 
cells from death must be different from that of mitogenesis. Although the two functions of 
bFGF clearly differ in their signal transduction, perhaps they are similar. For instance, since 
bFGF signal transduction is known to involve the phosphatidylinositol pathway, 
activation of different parts of the pathway may result in the production of multiple 
signals with variable functions. Some early response genes, which are activated 5 hours 
after exposure to bFGF, may be essential in initiating the mechanism for cell-death 
retrieval, whereas the delayed response genes may be critical for the cell proliferation 
mechanism. It is known that 3T3 cells release certain proteins wi thin 8 hours of exposure 
to bFGF. Perhaps these proteins serve as a self-defense mechanism and protect against cell 
death. 
Results of Cr51 Release Assay 
Average Percent Cr51 Retained 
Time Plus FGF Minus FGF 
TO 100 100 
T5 89.53 90.15 
I T10 86.2 80.5 
T15 81.5 69.6 
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